

REMARKS

In the Office Action under reply, claims 1-3 and 13 have been examined. Claims 1, 2, and 13 have been withdrawn as directed to non-elected subject matter. Claim 3 has been rejected under 35 U.S.C. §112, second paragraph, as indefinite.

Additionally, the Examiner has objected to the title.

With the above amendments, claims 1, 2, and 13 have been cancelled and claim 3 has been amended. Thus, only claim 3 remains pending in the application. The Examiner's rejection is addressed in full by the above-amendments.

THE AMENDMENTS TO THE CLAIMS

Claims 1, 2 and 13 have been canceled as drawn to non-elected subject matter. Cancellation of these claims is without prejudice, without intent to abandon any previously claimed subject matter, and without intent to acquiesce in any rejection of record.

Claim 3 has been amended to specify that R is or unsubstituted with one or more hydroxyl, carboxyl, phosphinyl, phosphonyl, sulfanyl, or sulfonyl substituents. Support for this amendment is found on page 11, lines 9 to 11 of the specification.

No new matter has been added.

THE PREVIOUSLY AMENDMENTS TO CLAIM 3

The Examiner requested that support be provided for the previous amendments to claim 3 wherein the term "aldehyde" was replaced with the language "5-hydroxyindole-3-acetaldehyde or 3,4-dihydroxyphenyl-acetaldehyde" and the term "neurotransmitter" was replaced with "serotonin or dopamine."

Support for these amendments is found generally through out the specification but can be specifically located in previously pending claims 5 and 6.

THE REJECTION UNDER 35 U.S.C. §112, SECOND PARAGRAPH

The Examiner has rejected claim 3 has indefinite citing the "substituted or unsubstituted" language used to describe the R moiety. As Applicants have amended claim 3 to clearly state the nature of the intended optional substituents, reconsideration and withdrawal of the rejection are in order and accordingly requested.

CONCLUSION

For the foregoing reasons, Applicant submits that the claims are in condition for allowance. A Notice of Allowance is requested, and a prompt mailing thereof would be much appreciated. Should the Examiner have any questions, he is invited to contact the undersigned attorney at (650) 384-8755.

Respectfully submitted,

Date: 4/30/07 By: J. Elin Hartrum
J. Elin Hartrum
Reg. No. 43,663
Customer No. 27716

CV Therapeutics, Inc.
3172 Porter Drive
Palo Alto, CA 94304
Tel: (650) 384-8755
Fax: (650) 475-0359

S:\LEGAL\CVT\Patent\Docs\Endowment\Endow 2\US\Div-01\Amendment Under 1.116 (2).DOC